Phase 2 Sleep Disorders Trial, Recruiting (NCT06028113)

Phase 2 Sleep Disorders Trial, Recruiting NCT06028113 Sponsor: Children's Hospital Medical Center, Cincinnati Condition: Sleep Disorders

Printed from Voxsanity (voxsanity.com.au) — NCT06028113 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Sleep Disorders

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The baby was born weighing 2,500 grams (about 5.5 pounds) or more
The baby was born between 37 and 42 weeks of pregnancy (considered full-term)
The caregiver speaks English
The baby receives primary care at the paediatric clinic running this trial
The family comes from a racial or ethnic minority background (non-white, or Hispanic or Latinx) and/or from an economically disadvantaged background (household income at or below 138% of the federal poverty level, or the family qualifies for Medicaid)

Who may not be able to join:

The baby spent more than 7 days in a Neonatal Intensive Care Unit (NICU)
The baby has a birth condition or newborn health issue that affects feeding, such as a cleft lip or palate, or a metabolic disorder
The baby was exposed to illicit drugs before birth (except for THC/cannabis)
The caregiver has significantly reduced cognitive functioning (confirm with trial site)
The family plans to move away from the area within the next year

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 14 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Tiffany Rybak, PhD, Children's Hospital Medical Center, Cincinnati

Phone: 513-517-7254

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06028113

Sponsor: Children's Hospital Medical Center, Cincinnati

Phase: Phase 2

Status: Recruiting

Condition: Sleep Disorders

Trial contact: 513-517-7254

More information: https://clinicaltrials.gov/study/NCT06028113

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The baby was born weighing 2,500 grams (about 5.5 pounds) or more
The baby was born between 37 and 42 weeks of pregnancy (considered full-term)
The caregiver speaks English
The baby receives primary care at the paediatric clinic running this trial
The family comes from a racial or ethnic minority background (non-white, or Hispanic or Latinx) and/or from an economically disadvantaged background (household income at or below 138% of the federal poverty level, or the family qualifies for Medicaid)

Who may not be able to join:

The baby spent more than 7 days in a Neonatal Intensive Care Unit (NICU)
The baby has a birth condition or newborn health issue that affects feeding, such as a cleft lip or palate, or a metabolic disorder
The baby was exposed to illicit drugs before birth (except for THC/cannabis)
The caregiver has significantly reduced cognitive functioning (confirm with trial site)
The family plans to move away from the area within the next year

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 14 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Children's Hospital Medical Center, Cincinnati

Registry

ClinicalTrials.gov

Start date

5 October 2023

Est. completion

30 November 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Conditional Weight Gain

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov